Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction.

Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1265-70. doi: 10.1016/j.bbmt.2009.06.001. Epub 2009 Aug 3.

2.

Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?

Hurley P, Konety S, Cao Q, Weisdorf D, Blaes A.

Biol Blood Marrow Transplant. 2015 Feb;21(2):300-4. doi: 10.1016/j.bbmt.2014.10.011. Epub 2014 Oct 16.

3.

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.

Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.

Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.

4.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

5.

Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.

Zhang XH, Xu LP, Liu DH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Wang Y, Zhao T, Chen Y, Fu HX, Liu KY, Huang XJ.

Clin Transplant. 2013 Jan-Feb;27(1):80-9. doi: 10.1111/ctr.12000. Epub 2012 Sep 2.

PMID:
22938074
6.

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho VT.

Biol Blood Marrow Transplant. 2015 May;21(5):873-80. doi: 10.1016/j.bbmt.2015.01.019. Epub 2015 Jan 23.

7.

Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.

Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.

Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. Epub 2007 Apr 23.

8.

[Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].

Wang CY, Ren HY, Qiu ZX, Wang Y, Cen XN, Wang LH, Wang MJ, Xu WL, Wang WS, Li Y, Dong YJ, Ou JP, Liang ZY, Liu W, Wang Q.

Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):659-63. doi: 10.3760/cma.j.issn.0253-2727.2013.08.004. Chinese.

PMID:
23978015
9.

Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.

Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, Fujisawa S, Sakamaki H, Aotsuka N, Yokota A, Kanda Y, Sakura T, Nanya Y, Saitoh T, Kanamori H, Takahashi S, Okamoto S.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1553-9. doi: 10.1016/j.bbmt.2014.06.005. Epub 2014 Jul 15.

10.

Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry.

Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Tanaka J, Kawa K, Kato K, Suzuki R, Morishima Y, Sakamaki H, Fukuda T.

Bone Marrow Transplant. 2013 Apr;48(4):529-36. doi: 10.1038/bmt.2012.172. Epub 2012 Sep 10.

PMID:
22964595
11.

Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.

Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92. doi: 10.1016/j.bbmt.2008.06.008.

12.

Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.

Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL, López-Anglada L, Rovira M, Bosch F, Carreras E, Corral LL, Sierra J, Valcárcel D.

Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.

13.

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB; Center for International Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.

14.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.

15.

Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.

Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1439-46. doi: 10.1016/j.bbmt.2009.07.013. Epub 2009 Sep 1.

16.

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.

Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties.

Blood. 2013 Jan 17;121(3):440-6. doi: 10.1182/blood-2012-08-448613. Epub 2012 Nov 30.

17.

Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M.

Biol Blood Marrow Transplant. 2012 Feb;18(2):289-94. doi: 10.1016/j.bbmt.2011.07.013. Epub 2011 Jul 23.

18.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

19.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ.

Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56.

20.

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG; Blood Marrow Transplant Clinical Trials Network (BMT CTN).

Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk